About this Special Issue
In recent years, the understanding of the molecular landscape of tumors of the central nervous system (CNS) has significantly expanded. It has been definitely clarified that tumors that appear to be histologically similar can have distinct epigenetic, genetic, transcriptomic, and proteomic characteristics and that clinical outcomes can be more accurately predicted by combining histological and molecular data rather than relying solely on histology. This has resulted in a novel classification of CNS tumors, published by the World Health Organization at the end of 2021, which integrates histological, genetic, and epigenetic information. However, many aspects remain to be clarified, including the significance of histopathological grading, or that of specific genetic alterations in several tumor types. Moreover, this remarkable advancement in our understanding of the molecular alterations in CNS tumors has not yet resulted in improved therapeutic strategies, which are essential to ensure the improved life expectancy of patients with these tumors.
This Special Issue welcomes contributions that improve our understanding of the molecular mechanisms of tumors of the CNS and their translation into clinical practice. Potential areas of interest may include, but are not limited to:
● Histopathological, genetic, and epigenetic prognostic factors in grade 1 and 2 meningiomas.
● Prognostic factors in IDH mutant and 1p/19q codeleted oligodendrogliomas.
● Diffuse gliomas with FGFR3:TACC3 fusion.
● Supratentorial ependymal tumors not elsewhere classified.
Even though abstract submission is not mandatory, we encourage all interested researchers to submit an abstract before submitting their manuscript. Abstracts do not have to coincide with the final abstract of the manuscripts. For authors, please review the journal's information regarding Author Guidelines and Article Processing Charges, or direct any questions to the Editorial Office: por@por-journal.com.
This Special Issue welcomes contributions that improve our understanding of the molecular mechanisms of tumors of the CNS and their translation into clinical practice. Potential areas of interest may include, but are not limited to:
● Histopathological, genetic, and epigenetic prognostic factors in grade 1 and 2 meningiomas.
● Prognostic factors in IDH mutant and 1p/19q codeleted oligodendrogliomas.
● Diffuse gliomas with FGFR3:TACC3 fusion.
● Supratentorial ependymal tumors not elsewhere classified.
Even though abstract submission is not mandatory, we encourage all interested researchers to submit an abstract before submitting their manuscript. Abstracts do not have to coincide with the final abstract of the manuscripts. For authors, please review the journal's information regarding Author Guidelines and Article Processing Charges, or direct any questions to the Editorial Office: por@por-journal.com.
Keywords: Glioma, Meningioma, Ependymoma, Grading
